Alkermes

‘We will not be proceeding with this land grab,’ says Minister of plan for Athlone area

Biopharma company reports sales of $156 million, down from $161 million in 2015

Companies looking after staff mental heath reap rewards

We can learn from other companies’ good practices

Government’s plan to revise border sparks opposition across the county and abroad

Shares dip as analysts says initial take-up of Irish group’s drug could be slow at first

Company gears up for new schizophrenia drug Aristada as opioid/alcohol therapy Vivitrol beats expectations

Heavy investment in R&D and set-up costs for new therapies push biopharma group to $30.6m loss

Company drops development of new pain therapy after missing targets in Phase 1 trial

Alkermes spinoff also delivers dividend for drug technology group

Shares in US pharmacy Walgreens also hit as it passes up opportunity for Swiss base

Apollo Aviation will move to top floor of block previously occupied by Anglo

Dublin-based pharma group says it’s not in line for takeover driven by Ireland’s low tax regime

A round-up of business events happening this week

Company will seek US marketing approval for long-acting injectible aripiprazole lauroxil

Biopharma group bullish on prospects for pipeline and existing portfolio this year

Athlone project will create 50 high-skilled full-time jobs when completed by 2016.

Centra, Rossport Pharmaceutical and Alexion among firms planning expansion

An inspired approach to clinical trial data is fuelling the firm’s assault on central nervous system ailments

Group of investment firms looking at investment opportunities in Europe

Company brings fiscal year in line with calendar

Falling sales and generic competition blamed for cutbacks

Irish biopharma group transfers ownership of MS drug to US partner for $3.25bn